Overview

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Status:
Completed
Trial end date:
2013-12-12
Target enrollment:
Participant gender:
Summary
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone. This clinical study compared cariprazine + ADT with placebo + ADT in outpatients with a diagnosis of MDD and an inadequate response to ADT. The study consisted of approximately 2 weeks of screening and washout followed by 8 weeks of double-blind treatment followed by a 1 week safety follow-up.
Phase:
Phase 2
Details
Lead Sponsor:
Forest Laboratories
Collaborator:
Gedeon Richter Ltd.
Treatments:
Cariprazine